U.S. revenue in the fourth quarter of 2024 was $91.4 million, a decrease of 9.9% compared with $101.5 million in the prior year period. U.S. permanent implant procedures decreased by 7.0% compared ...
Nevro also offers minimally invasive treatment options for patients suffering from chronic sacroiliac (SI) joint pain. SENZA, SENZA II, SENZA OMNIA, OMNIA, HF10, the HF10 logo, 10 kHz Therapy ...
Nevro also offers minimally invasive treatment options for patients suffering from chronic sacroiliac (SI) joint pain. SENZA, SENZA II, SENZA OMNIA, OMNIA, HF10, the HF10 logo, 10 kHz Therapy ...
Nevro Corp. NVRO reported a loss per share of 64 cents in the fourth quarter of 2024, wider than the year-ago quarter’s loss of 15 cents. The Zacks Consensus Estimate is pegged at a loss per ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果